Prostate Brachytherapy Sources Vary By $5,570, Violate 2X Rule – CAB Data
This article was originally published in The Gray Sheet
Executive Summary
Brachytherapy seeds for prostate cancer should be reimbursed by Medicare on a per-seed basis under the hospital outpatient prospective payment system, the Coalition for the Advancement of Brachytherapy (CAB) contends in Sept. 24 comments to CMS